Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @https://www.alliedmarketresearch.com/request-sample/3643
Filgrastim market was valued at $ 562.50 million in 2020 and is projected to reach $745.90 million by 2030 registering a CAGR of 2.80% from 2021 to 2030. Filgrastim is a recombinant DNA-derived granulocyte colony stimulating factor (G-CSF) that is commonly used to treat low blood neutrophils. It’s also commonly employed in cases where lukapheresis is associated with an increase in white blood cells. Filgrastim has a number of side effects, including joint discomfort, chest pain, hair loss, and vomiting.
Filgrastim is a recombinant form of natural G-CSF that stimulates the production of neutrophils. It was licensed for the treatment of low blood neutrophils in the United States in 1991. The World Health Organization (WHO) has declared filgrastim in the list of essential drugs as safe and effective drugs. Filgrastim was first developed by Amgen, Inc. and sold under the brand name Neupogen. A large number of biosimilar companies are involved in the manufacturing and marketing of Filgrastim across the world. Filgrastim costs about $200 in the US, around €50 in the UK, and $100 in developing countries.
Factors such as increase in various diseases and increasing geriatric population are driving the growth of filgrastim market. In addition, the increasing pressure to reduce healthcare expenditure and increasing availability of filgrastim, due to its cost, is expected to boost the growth of this market. In addition, the increased demand for biosimilars in the treatment of neutropenia further erodes the market. However, the most common side effects of filgrastim include joint pain, chest pain, hair loss, and nausea which inhibits growth. On the other hand, increased investment in R&D programs for the development of effective and innovative biosimilars will provide more market opportunities.
In addition, this drug is used to treat neutropenia, a condition that occurs when the bone marrow is converted to chemotherapy. It is used to treat various diseases as a complementary therapy. Over the past decade, there has been a significant increase in cancer prevention in developed countries, with government-led campaigns to raise awareness for early treatment. These factors are expected to drive the global market for filgrastim. Approved biosimilars such as Grafeel, Colstim, Neukine and Filcad which are cheaper and readily available in developing countries are expected to boost the growth of the global Filgrastim market.
Access Complete Copy of this Report (Including the full TOC, Tables and Figures, Graphs as well as Chart) @https://www.alliedmarketresearch.com/purchase-enquiry/3643
Key Market Segments
By Drug Type
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Chemotherapy induced Neutropenia
- Chronic Neutropenia
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA